We use our own and third party cookies in order to improve our performance, and to obtain anonymous statistics about the use of the website. By continuing to browse, you authorize their use. In order to change the preferences and to obtain further information, please refer to our cookies policy.

Areas
Menu
en

LetiFend®: vaccine against canine leishmaniasis

Safety

Excellent tolerability shown in a wide range of breeds and ages.

Efficacy

72% prevention of canine leishmaniasis in areas at high risk of infection by Leishmania infantum.

Convenience

A single annual dose confers immunity for 365 days.

Speed

Protection against development of the disease from 28 days after vaccination.

Reliability

Specific immune response to vaccination that does not interfere with the serological diagnosis of the disease.

Efficacy confirmed in laboratory studies

Different laboratory studies conducted with experimental infection with Leishmania infantum showed that LetiFend®:

  • Reduces development of the disease.
  • Reduces clinical signs.
  • Reduces parasite load in the spleen and lymph glands.
  • Protects from 28 days.
  • Duration of immunity: 1 year.

LetiFend® reduces the risk of developing clinical leishmaniasis

A dog vaccinated with LetiFend® presents:

Vaccination with LetiFend® does not interfere with the diagnosis of leishmaniasis

LetiFend®, a DIVA (Differentiating Infected from Vaccinated Animals) vaccine which allows discrimination between vaccinated and infected animals.

  • Serums of animals vaccinated with LetiFend® were subject to the serological tests most widely used for the diagnosis of Leishmaniasis (ELISA, IIF and snap tests).
  • The results showed that none of the evaluated tests were positive after analysis of the serums.

LetiFend® enables the vaccination of a population of animals susceptible to catching the disease without compromising their subsequent serological diagnosis.

Recombinant technology: innovation in prevention

Recombinant vaccines are part of a new strategy and have been designed to ensure a targeted and effective immune response with a high level of safety.

Discover how protein Q, the active substance in the LetiFend® vaccine, was developed

Innovation against canine Leishmaniasis

  • LetiFend®, a product obtained through recombinant DNA technology, the active substance of which is Protein Q.
  • Protein Q, the active substance in LetiFend®, is a protein obtained by a combination of 5 highly antigenic fragments, fused and cloned in E. coli, from 4 Leishmania infantum proteins.